| Trial ID: | L4253 |
| Source ID: | NCT05093517
|
| Associated Drug: |
Remd-477
|
| Title: |
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes|Glucose Tolerance Impaired|Insulin Sensitivity
|
| Interventions: |
DRUG: REMD-477|DRUG: Placebo Subcutaneous injection
|
| Outcome Measures: |
Primary: Glycated Hemoglobin (HbA1c), Change in HbA1c measured at baseline and after intervention administration, Baseline to 13 weeks|Fasting Plasma glucose (FPG), Change in fasting plasma glucose measured at baseline and after intervention administration, Baseline to 13 weeks|Plasma glucose (PG), Change in plasma PG measured at baseline and after intervention administration using an oral glucose tolerance test (OGTT), Baseline to 13 weeks|Hepatic insulin sensitivity, Change in hepatic glucose production (HGP), Baseline to 13 weeks|Whole body glucose disposal, Change in whole body glucose disposal measured in mg/kg/min, Baseline to 13 weeks|Plasma Free Fatty Acids (FFA), Change in plasma free fatty acids, Baseline to 13 weeks|Muscle Insulin sensitivity, Change in muscle insulin sensitivity measured by insulin-stimulated glucose uptake during low dose high dose insulin clamp., Baseline to 13 weeks |
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
4
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (PARTICIPANT)|Primary Purpose: TREATMENT
|
| Start Date: |
2021-11-10
|
| Completion Date: |
2022-03-16
|
| Results First Posted: |
|
| Last Update Posted: |
2024-08-09
|
| Locations: |
Texas Diabetes Institute, San Antonio, Texas, 78207, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05093517
|
